Company: NUTR
Filing Date: 2025-03-25
Form Type: CORRESP
Source: 0001641172-25-000449
Chunk: 59

Company: NUSATRIP Inc
Filing Date: 2025-03-25
Form: CORRESP
Chunk 59
---
 to investors.

We are currently a “smaller reporting company”,
meaning that we are not an investment company, an asset- backed issuer, or a majority-owned subsidiary of a parent company that is not
a smaller reporting company and annual revenues of less than $50.0 million during the most recently completed fiscal year. In the event
that we are still considered a “smaller reporting company,” at such time as we cease being an “emerging growth company,”
we will be required to provide additional disclosure in our SEC filings. However, similar to an “emerging growth companies”,
“smaller reporting companies” are able to provide simplified executive compensation disclosures in their filings; are exempt
from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting firms provide
an attestation report on the effectiveness of internal control over financial reporting; and have certain other decreased disclosure obligations
in their SEC filings, including, among other things, only being required to provide two years of audited financial statements in annual
reports. Decreased disclosures in our SEC filings due to our status as a “smaller reporting company” may make it harder for
investors to analyze our results of operations and financial prospects.

| 35 |

The offering price of our shares of Common Stock offered in the Resale Prospectus Resale is fixed.

The Selling Stockholders set forth in the Resale Prospectus
will offer and sell their shares of Common Stock being offered under the Resale Prospectus at $4.50 per share for the duration of the
offering or until the shares are listed on a national securities exchange at which time the shares offered under the Resale Prospectus
may be sold at prevailing market prices or privately negotiated prices or in transactions that are not in the public market.

Conversion of the Convertible Notes and issuance of incentive stock grants shall have a dilutive effect on our stock, and negatively impact the price of our Common Stock.

To the extent that the Convertible Notes are converted
(See “Description of Capital Stock-Convertible Notes”) and options described in this prospectus (See “Description of Capital Stock-Equity Incentive Plan”) are exercised, dilution to the interests of our stockholders will occur.

Pursuant to the amendments to the securities purchase agreement for Convertible Notes dated November 13, 2024, entered by the Company and the investors, the Convertible Notes shall automatically convert into shares of our common stock upon the effectiveness of